Adrenal Sarcoma
Adrenal Sarcoma - Related Videos
12:44
The In ovo CAM-assay as a Xenograft Model for Sarcoma
0 Views •
Cited by 64 •
2013
The in ovo chorioallantoic membrane (CAM) is grafted with fresh sarcoma-derived tumor tissues, their single cell suspensions, and permanent and transient fluorescently labeled established sarcoma cell lines. The model is used to study graft- (viability, Ki67 proliferation index, necrosis, infiltration) and host (fibroblast infiltration, vascular ingrowth) behavior.
11:42
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
0 Views •
Cited by 7 •
2017
We present here a cell culture method for inducing mesenchymal-epithelial transitions (MET) in sarcoma cells based on combined ectopic expression of microRNA-200 family members and grainyhead-like 2 (GRHL2). This method is suitable for better understanding the biological impact of phenotypic plasticity on cancer aggressiveness and treatments.
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
0 Views •
Cited by 44 •
2017
'Super-selective' adrenal venous sampling (ssAVS, also called segmental adrenal venous sampling: sAVS) was performed using a micro-catheter to identify adrenal segment(s) that produce excessive amounts of hormones. The ssAVS technique was described, cases in which adrenal segmental lesion(s) were identified by ssAVS were presented, and the usefulness of ssAVS in future adrenal research was discussed.
07:02
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)
0 Views •
Cited by 6 •
2010
Host cell factors play a critical role in the establishment and maintenance of Kaposi's sarcoma (KS). We outline methods to identify host cell factors altered in KSHV-infected DMVEC cells, and in KS tumor tissue. Cellular genes altered by virus will serve as potential target(s) for novel therapeutics.
08:02
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
0 Views •
Cited by 6 •
2016
Adrenal activity can be assessed in the equine species by analysis of feces for corticosterone metabolites. The method offers a non-invasive option to assess long term patterns in both domestic and free ranging horses. This protocol describes the enzyme linked immunoassay involved and the associated biochemical validation.
FAQs
Its rarity and aggressive behavior can make initial interpretation challenging, particularly when the mass involves the adrenal gland and nearby tissues. Imaging can demonstrate the lesion and its extent, but it may not establish the precise sarcoma subtype or origin. Histopathology and immunohistochemistry therefore provide complementary evidence for more accurate classification.
Adrenal sarcoma may invade structures adjacent to the adrenal region as the tumor enlarges. Abnormal cells can also disseminate through blood or lymphatic pathways, creating disease beyond the primary mass. Recognizing both local invasion and potential distant spread is important because tumor extent influences assessment of resectability and the overall treatment plan.
Histopathology examines the tumor’s cellular features, while immunohistochemistry evaluates markers that help clarify its type and origin. These methods are especially important when imaging shows a mass but cannot fully identify its nature. Their findings support distinction among tumor subtypes and help clinicians connect the diagnosis with an appropriate, individualized management strategy.
The location and extent of disease help determine whether complete removal is feasible. A confined, technically removable tumor may be approached differently from one that has invaded nearby structures or spread through blood or lymphatic routes. This assessment links diagnostic findings with decisions about surgery and whether additional systemic therapy or radiation should be considered.
Evaluation begins with imaging to identify the lesion and assess its anatomic extent. Tissue assessment then uses histopathology and immunohistochemistry to clarify the tumor’s subtype and origin. Together, these stages provide structural and diagnostic information that clinicians use to judge resectability, characterize the disease, and select a management approach suited to the individual case.
Surgery is often central when complete tumor removal is feasible. If the disease cannot be fully removed, has greater extent, or presents features requiring additional control, systemic therapy or radiation may be considered in selected cases. The choice depends on the sarcoma subtype, the spread and local involvement of the tumor, and its resectability.